Our aim is for every person who needs our diagnostic tests to be able to benefit from them.
Ensuring patients have access to healthcare is a shared responsibility requiring many stakeholders to work together. The Medicare Benefits Schedule (MBS) has delivered broad access to diagnostic tests for generations of Australians, and Roche recognises the importance of their roles. Roche supports the continued reform of these schemes to ensure the value of each medicine and diagnostic test is assessed on a broad range of factors, such as improved health outcomes, productivity gains, healthcare efficiency and addressing an unmet need.
We believe that continued investment in the MBS needs to be sustainable, and growth should be in line with the economic resources of Australia and the needs of an ageing population.
We are focused on increasing broad access to medicines and diagnostic tests, as well as providing support to patients in the following areas:
Severin Schwan
CEO of Roche Group
09441751001_00000000_02
